Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT). Both saw their shares more than double in 2024, ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of $125.00. Justin Zelin has given his Buy rating due to a ...

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...

You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy ... 1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials.

Eli Lilly, which manufactures Mounjaro for diabetes and Zepbound for weight loss, did not respond to USA TODAY's request for comment about the research. This story was updated to add new information.